Evidence map›Paper›PMID 34997176›Full record

ArticleScientific reports2022

Population-based survival for cancer patients in Saudi Arabia for the years 2005-2009.

Mohamed Aseafan, Edward Devol, Mahmoud AlAhwal, Riad Souissi, Reham Sindi, Haya AlEid, Shouki Bazarbashi

Abstract readHistorical Article
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mohamed AseafanSection of Medical Oncology, Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, 11211, Saudi Arabia.
Edward DevolDepartment of Biostatistics, Epidemiology and Scientific Computing, King Faisal Specialist Hospital and Research Center, Riyadh, 11211, Saudi Arabia.
Mahmoud AlAhwalDepartment of Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Riad SouissiResearch Department, Elm Company, Riyadh, Saudi Arabia.
Reham SindiDepartment of Biostatistics, Epidemiology and Scientific Computing, King Faisal Specialist Hospital and Research Center, Riyadh, 11211, Saudi Arabia.
Haya AlEidDepartment of Therapeutic Services, Ministry of Health, Riyadh, Saudi Arabia.
Shouki BazarbashiSection of Medical Oncology, Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, 11211, Saudi Arabia. bazarbashi@kfshrc.edu.sa.ORCID 0000-0002-8913-8158

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Saudi Cancer Registry reported in 2007 the 5-year observed survival for the most common cancer sites for the years 1994-2004. In this report we looked at the cancer survival in the period 2005-2009 and evaluated the trend over the 15 years period from 1994 to 2009. Cases of the top 14 cancer sites reported by the population based Saudi Cancer Registry from 1 January 2005 to December 31, 2009, were submitted for survival analysis. The vital status of those patients was collected. Analysis of survival for the above period was compared with the prior reported 2 periods (1994-1999, 2000-2004). In addition, analysis was done according to age, sex, disease stage and the province. Data of 25,969 patients of the commonest cancer sites were submitted. Of those 14,146 patients (54%) had complete demographic data available and vital status was reported. Thyroid cancer had the highest 5- year observed survival of 94% (95% confidence interval (CI) 93-95%)), followed by Breast (72%, 95% CI 71-74%). In hematological malignancies, Hodgkin's Lymphoma had the highest 5-year survival of 86% (95% CI 84-88%). Survival rates has improved in most of the cancers sites for the studied periods except for lung, uterine and Hodgkin's lymphoma which plateaued. Our study confirms a steady improvement in the 5-year observed survival over time for the majority of cancers. Our survival data were comparable to western countries. This data should be used by policy makers to improve on cancer care in the kingdom.

Indexed as

AdultAgedAge FactorsFemaleHistory, 20th CenturyHistory, 21st CenturyHumansMaleMiddle AgedNeoplasmsSaudi ArabiaSex FactorsSurvival AnalysisSurvival RateYoung Adult

Identifiers

PMID34997176
PMCPMC8742104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.